US4490291A - Nonapeptide amides - Google Patents

Nonapeptide amides Download PDF

Info

Publication number
US4490291A
US4490291A US05/596,810 US59681075A US4490291A US 4490291 A US4490291 A US 4490291A US 59681075 A US59681075 A US 59681075A US 4490291 A US4490291 A US 4490291A
Authority
US
United States
Prior art keywords
tyr
trp
leu
ala
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/596,810
Inventor
Masahiko Fujino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP8338973A external-priority patent/JPS5035158A/ja
Priority claimed from JP49031734A external-priority patent/JPS5749532B2/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of US4490291A publication Critical patent/US4490291A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/13Luteinizing hormone-releasing hormone; related peptides

Definitions

  • the present invention relates to novel nonapeptide amide derivatives having strong ovulation inducing activity, which are represented by the formula:
  • R 1 is His, Tyr, Trp or p-NH 2 --Phe
  • R 2 is Tyr or Phe
  • R 3 is Leu, Ile or Nle
  • R 4 is alkyl of 1 to 3 carbon atoms which may be substituted with hydroxyl group.
  • the present invention relates also to a method for producing the nonapeptide amide derivatives (I).
  • amino acids and peptides are designated by abbreviations which are in common usage in the particular field of art or which have been approved by Committee on Biochemical Nomenclature of IUPAC-IUB. Amino acid is in the L-configuration unless otherwise designated.
  • Trp Tryptophan
  • the straight or branched alkyl group of 1 to 3 carbon atoms which may be substituted with hydroxyl group is exemplified by methyl, ethyl, n-propyl, i-propyl, hydroxy-methyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-n-propyl, 3-hydroxy-n-propyl, 2,2-dihydroxy-i-propyl or the like.
  • hypothalamus contains factors which, at a higher level, control the secretion of tropic hormones from the pituitary.
  • TRH thyrotropin-releasing hormone
  • a hormone which promotes the secretion of luteinizing hormone has been extracted in pure form from pigs and sheep and shown to be a decapeptide of the structure: H--(Pyr)Glu--His--Trp--Ser--Tyr--Gly--Leu--Arg--Pro--Gly--NH 2 .
  • the present inventor has succeeded in synthesizing nonapeptide amide derivatives (I) and has surprisingly found that these compounds have more potent ovulation inducing activity than the naturally-occurring decapeptide. It has been also found by the present inventor that those compounds act upon the pituitary to promote the secretion of both luteinizing hormone and follicle-stimulating hormone. The present inventor further has found that those compounds are useful not only as drugs for human beings, e.g. drugs for diagnosis of the pituitary function or the gonadotropin deficiency and therapy of amenorrhea, but also as veterinary drugs particularly for the purpose of the animal breeding. The present invention is the culmination of those unexpected findings.
  • Another object of the present invention is to provide a method for the production of the nonapeptide amide derivatives (I).
  • the nonapeptide amide derivative (I) is produced by a method characterized by that a reagent (A)--L-pyroglutamic acid or a peptide fragment which has a L-pyroglutamic acid unit (i.e. H--(Pyr)Glu--) at its N-terminal end and at the same time which, from thereon, comprises the above amino acid sequence--is condensed with a reagent (B)--an amine component which corresponds to the balance of the nonapeptide amide derivative (I)--, said two reagents (A) and (B) being optionally protected by protecting group or groups, and then the protecting group or groups if any are removed.
  • a reagent (A)--L-pyroglutamic acid or a peptide fragment which has a L-pyroglutamic acid unit i.e. H--(Pyr)Glu--
  • the reagent (A) is L-pyroglutamic acid or a peptide fragment which has an L-pyroglutamic acid unit at its N-terminal end and at the same time which from thereon comprises amino acid sequence of formula (I)
  • the reagent (B) to be condensed with the reagent (A) is an amine component which corresponds to the balance of the nonapeptide amide derivative (I), the reagents (A) and (B) being optionally protected.
  • R is an alkoxy group (e.g. methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, etc.), an aralkyloxy group (e.g. benzyloxy, etc.) or amino] is easily converted to the L-pyroglutamyl group itself: ##STR1## by the contact with a base (e.g. ammonia, etc.) or an acid (e.g. acetic acid etc.) and that the group (II) is equivalent to L-pyroglutamyl group itself in this respect.
  • a base e.g. ammonia, etc.
  • an acid e.g. acetic acid etc.
  • H--(Pyr)Glu--) of the reagent (A) includes not only the L-pyroglutamyl group itself but also the protected L-glutamyl group of the formula (II).
  • H--(Pyr)Glu-- of the reagent (A) represents the group (II)
  • the group (II) is easily converted to L-pyroglutamyl group itself in accordance with per se known means.
  • the condensation reaction according to this invention can be carried out by condensing means known for the formation of peptide linkages.
  • condensing means known for the formation of peptide linkages.
  • means of condensation are the azide process, chloride process, acid anhydride process, mixed acid anhydride process, DCC process, active ester process, Woodward reagent K process, carbodiimidazole process, oxidation-reduction process, DCC/HONB process and others [The Peptides, Vol. 1 (1966), Schroder and Lubke, Academic Press, New York, U.S.A. and Belgian Pat. No. 796,399].
  • carboxyl and amino groups which should not be involved in the contemplated reaction or activate the carboxyl or/and amino groups which will take part in the reaction, by means which are known per se.
  • the carboxyl groups in the starting material may be protected in the form of metal salts (e.g. sodium and potassium salts) or esters (e.g. methyl, ethyl, benzyl, p-nitrobenzyl, t-butyl or t-amyl esters).
  • Protective groups for amino groups in the starting materials may be any of conventional protecting groups of amino groups in peptide synthesis, e.g. benzyloxycarbonyl, t-butoxycarbonyl, isobornyloxycarbonyl, etc.
  • the hydroxyl group of serine may be protected with a conventional protective group such as benzyl, t-butyl and other ether-forming groups.
  • the hydroxyl group of tyrosine may be protected with benzyl, t-butyl and other ether-forming groups; the guanidino group of arginine may be protected with such groups as nitro, tosyl, carbobenzoxy, isobornyloxycarbonyl or adamantyloxycarbonyl.
  • activated carboxyl groups in starting materials there may be mentioned the corresponding acid anhydride, azide, active esters [esters with alcohols (e.g. pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethyl alcohol, p-nitrophenol, N-hydroxy-5-norbornene-2,3-dicarboximide, N-hydroxysuccinimide, N-hydroxyphthalimide or N-hydroxybenztriazole], etc.
  • the activated amino groups in starting materials may for example be the corresponding phosphoric acid amide.
  • This reaction may be conducted in the presence of a solvent.
  • the solvent can be selected from those known to be useful for peptide condensation reactions.
  • anhydrous or aqueous dimethylformamide, dimethylsulfoxide, pyridine, chloroform, dioxane, dichloromethane, tetrahydrofuran and suitable mixtures of such solvents may be mentioned by way of example.
  • the reaction temperature is selected from within the range known to be employable for reactions leading to the formation of peptide bonds, i.e. normally within the range of about -20° C. to about 30° C.
  • the precursor materials (protected peptides) of the contemplated compounds according to this invention may also be easily prepared by solid-phase synthetic processes.
  • routine procedures are catalytic reduction in the presence of a catalyst such as palladium black, palladium-on-carbon, platinum or the like, hydrolysis by means of hydrogen fluoride, trifluoroacetic acid or the like, and reduction with metallic sodium in liquid ammonia.
  • a catalyst such as palladium black, palladium-on-carbon, platinum or the like
  • hydrolysis by means of hydrogen fluoride, trifluoroacetic acid or the like hydrolysis by means of hydrogen fluoride, trifluoroacetic acid or the like, and reduction with metallic sodium in liquid ammonia.
  • the peptide (I) thus produced can be recovered from the reaction product mixture by procedures known for the recovery of peptides, e.g. by extraction, distribution, column chromatography, etc.
  • the peptide (I) may also be recovered in the form of a salt or metal complex compound.
  • acids which are able to form salts with peptide (I) there may be mentioned inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, etc. and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranylic acid, cinnamic acid, naphthalenesulfonic acid or sulfanylic acid, for instance.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, etc.
  • organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, mal
  • the metals which are able to form metal complex compounds with peptide (I) include, among others, zinc, nickel, cobalt, copper and iron.
  • a metal complex compound can be produced by conventional procedures, for example, by reacting peptide (I) with the hydroxide or oxide of a metal of the above-mentioned variety at pH about 6 to 8.
  • polypeptides (I) have LH-RH (luteinizing hormone releasing hormone) activity and, accordingly, are able to promote the secretion of LH (luteinizing hormone) and FSH (follicle stimulating hormone). Therefore, polypeptides (I) are of use as drugs for promoting ovulations in women and other animals (e.g. rats, ewes, pigs, cows, mares, quails or hens). The peptides can also be used for other pharmaceutical purposes for which conventional LH-RH, LH and FSH preparations have been employed.
  • LH-RH luteinizing hormone releasing hormone
  • FSH follicle stimulating hormone
  • LH-RH activity of polypeptides (I) is about 20 times that of known naturally-occurring LH-RH, their dosage may be determined for each application on the basis of the above multiple whilst other factors (e.g. the subject of administration of the kind of disease) are also taken into consideration.
  • a suitable dosage may be selected from within the range of about 2 ng. to 2 ⁇ g. daily per kilogram of body weight.
  • Polypeptides (I) are primarily administered non-orally (e.g. by injection or by the rectal or vaginal route), although they are orally administered in certain instances.
  • the dosage forms employable include, for example, injections, suppositories, pessaries and powders.
  • the injections can be prepared by dissolving about 10 ⁇ to 100 ⁇ of polypeptide (I) in 1 ml. of physiological saline.
  • Polypeptides (I) can be also made into lyophilized ampoule products with mannitol added as an excipient so that one may adminster them as injections for extemporaneous use.
  • the starting material peptides employable in the method of this invention can be prepared either by known processes for peptide synthesis or by utilizing such processes as found necessary.
  • Ovulation-inducing activity is determined in Sprague-Dawley rats (4-day cycling female) in which the injection of the compound was made subcutaneously at 14:30 on the day of diestrous, and the ovulated ova in the ampilla of the oviduct were examined on the morning of the next day.
  • the results (ED 50 ) were compared with that (ED 50 ) of LH-RH itself.
  • the assay results on the object compounds are as follows.
  • Celite Filter aid manufactured by Johns-Manville, U.S.A.
  • Biogel P-2 Materials for gel filtration manufactured by BIO.RAD, U.S.A.
  • Cephadex LH-20 Esterified dextran gel manufactured by Pharmacia Fine Chemicals, Sweden
  • the insolubles are filtered off and the filtrate is run onto a column (1 cm diameter ⁇ 5 cm) of Amberlite IRA-410 (acetate form), which is then washed with 50 ml. of water.
  • the effluent and washings are pooled and run onto a column (1.5 cm diameter ⁇ 25 cm) of carboxymethyl-cellulose. Elution is carried out by the gradient method using 0.005M ammonium acetate (300 ml.) and 0.175M ammonium acetate (300 ml.).
  • the 170 ml.- to 240 ml.-fractions are pooled and lyophilized, whereupon 208 mg. of white fluffy powder is obtained.
  • polypeptide-amide of formula (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NHCH 3 is obtained using, as one of the starting materials, Z--(D)--Ala--Leu--Arg(NO 2 )--Pro--NH--CH 3 instead of Z--(D)--Ala--Leu--Arg(NO 2 )--Pro--NH--CH 2 --CH 3 in the above (b).
  • This product has the following physical and chemical properties.
  • the dimethylformamide is distilled off under reduced pressure and the residue is dissolved in 20 ml. of water.
  • the small amount of insolubles (dicyclohexyl-urea) is filtered off and the filtrate is run onto a column (1 cm diameter ⁇ 4 cm) of Amberlite IRA-410 (acetate form), which is then washed with water.
  • the effluent and washings are pooled and run onto a column (1.5 cm diameter ⁇ 25 cm) of carboxymethylcellulose.
  • the product is dissolved in 5 ml. of dimethylformamide, followed by the addition of 230 mg. of Z--(D)--Ala--OH and 210 mg. of HONB. After cooling with ice, 0.16 ml. of triethylamine and, 230 mg. of DCC are added in this order. The mixture is stirred under cooling with ice for 1 hour and, then, at room temperature for 4 hours. The reaction mixture is filtered and the filtrate is added to 100 ml. of chloroform. The solution is washed with a 4% aqueous solution of sodium bicarbonate and, then, with water, dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure.
  • Amino acid analysis (hydrolysis with 5.7N hydrochloric acid in the presence of thioglycolic acid): His, 1.00; Arg, 0.98; Trp, 0.98; Ser, 0.92; Glu,1.00; Pro, 1.00; Ala, 0.99; Leu, 1.00; Tyr, 0.98 (87% recovery).
  • the resultant dicyclohexylurea is removed by filtration and the filtrate is concentrated to dryness under reduced pressure. The residue is triturated with ethyl acetate and the resultant powder is collected by filtration. Yield: 6.7 g.
  • the powder is dissolved in 30 ml. of a mixture of methanol and chloroform (15:85) and the solution is run onto a column (6 cm diameter ⁇ 12 cm) of silica gel prepared with a mixture of methanol and chloroform (15:85). The column is eluted with 600 ml. of a mixture of methanol and chloroform (15:85), 1 l. of a mixture of methanol and chloroform (25:75) and 1 l.
  • the column is washed with water and subjected to a gradient elution with 300 ml. of water and 300 ml. of 100% ethanol.
  • the object compound emerges in the 130 ml.- to 220 ml.-fractions, which are pooled and concentrated under reduced pressure to evaporate the ethanol.
  • the residue is run onto a column (2 cm diameter ⁇ 30 cm) of carboxymethyl-cellulose.
  • the column is subjected to a gradient elution with ammonium acetate of from 0.005 to 0.2M (pH 6.8).
  • the object compound emerges in 350 ml.- to 500 ml.-fractions, which are pooled and lyophilized to yield fluffy powder. Yield 112 mg.
  • the compound which is produced just above is identical in Rf value, specific rotation and ED 50 value of ovulation inducing activity with the compound which is produced by the process of the above (I).
  • the urea compound which is separated is removed by filtration.
  • the filtrate is added to a solution of the above produced precipitates in 1 ml. of dimethylformamide, followed by the dropwise addition of 0.28 ml. of triethylamine.
  • the mixture is stirred for 12 hours and subjected to distillation to evaporate the solvent.
  • the residue is extracted with 100 ml. of chloroform.
  • the extract is washed with 5% aqueous solution of sodium bicarbonate, water, 0.5N hydrochloric acid and water in this order and dried over anhydrous sodium sulfate.
  • the chloroform is evaporated by distillation.
  • BOC--Pro--resin (proline content: 0.314 millimol/g) is supplied to a reactor of peptide automatic synthesizer (APS-800 made by Shimidzu Seisakusho, Ltd., Japan) and swelled with dichloromethane for 12 hours and amino acids are introduced in the following cycle.
  • APS-800 made by Shimidzu Seisakusho, Ltd., Japan
  • the powder is dissolved in a mixture of ethyl acetate, pyridine, acetic acid and water (60:20:6:10) and the solution is run onto a column (3 cm diameter ⁇ 20 cm) of silica gel which is prepared with the same kind of the solvent mixture.
  • the column is eluted with the same kind of the solvent mixture.
  • Fractions showing Rf value of 0.4 on thin layer chromatography on silica gel with methanol-chloroform (15:85) are pooled and concentrated to dryness under reduced pressure.
  • the residue is triturated with ethyl acetate and the resultant powder is collected by filtration. Yield 240 mg.
  • the powder is dissolved in 5 ml. of hydrogen fluoride containing 0.05 ml.
  • the residue is dried over sodium hydroxide under reduced pressure in a desiccator.
  • the precipitated dicyclohexylurea is filtered off, and the amine component (H--Tyr(OBzl)--(D)--Ala--OBzl) previously prepared is dissolved in the filtrate.
  • the solution is cooled to 0° C. and 4.2 ml. of triethylamine is added dropwise. The solution is stirred at room temperature for 5 hours, after which the tetrahydrofuran is distilled off under reduced pressure.
  • the water layer is rendered acidic with 1N hydrochloric acid and extracted with 100 ml. of n-butanol.
  • the extract is washed with water and the n-butanol is distilled off.
  • the trifluoroacetic acid is distilled off and the residue is triturated with ether and thoroughly dried over sodium hydroxide in a desiccator.
  • This powder and 81 mg. of HONB are dissolved in the previously prepared dimethylformamide solution, followed by cooling to -2° C.
  • 93 mg. of DCC and 0.05 ml. of N-ethylmorpholine are added and the resultant mixture is stirred at 0° C. for 2 hours and, then, at room temperature overnight.
  • the precipitated urea compound is filtered off and 50 ml. of ether is added to the filtrate.
  • the precipitate is recovered by filtration. Yield 350 mg.
  • This product is passed over 7 g. of silica gel using the developer solvent mixture of Rf 1 .
  • the product is dissolved in 5 ml. of dimethylformamide and the solution is neutralized with 0.1 ml. of N-ethylmorpholine.
  • the water solution is passed columnwise over Amberlite IR-410 (acetate form, 0.9 cm diameter ⁇ 15 cm) and the effluent and aqueous washings are pooled and lyophilized.
  • the product is dissolved in 0.005M ammonium acetate buffer and run onto a column (1.8 cm diameter ⁇ 19 cm) of carboxymethyl-cellulose. Elution is carried out by the linear gradient method using 0.005M (300 ml.) to 0.2M (300 ml.) ammonium acetate buffer and the 90 ml.- to 140 ml.-fractions are pooled and lyophilized. Yield 170 mg.
  • BOC--Ser--Tyr--(D)--Ala--Leu--Arg(NO 2 )--Pro--NH--CH 2 CH 3 (670 mg) is treated with trifluoroacetic acid (10 ml) at room temperature for 20 minutes, and to this solution is added dry ether (50 ml) to yield a fine solid which is dried over NaOH-pellets in vacuo.
  • the resulting powder is dissolved in dimethylformamide (5 ml) and to this solution is added triethylamine (0.11 ml) together with BOC--Trp--ONB which is prepared from BOC--Trp--OH (243 mg) and HONB (150 mg) by the DCC method.
  • the powder obtained is dissolved in dimethylformamide (2 ml) together with N-ethylmorpholine (0.06 ml), and to this are added the above described free acid and HONB (102 mg). The mixture is cooled to 0° C. and to this is added DCC (110 mg). The solution is stirred for 2 hours at 0° and for additional 10 hours at room temperature. The reaction mixture is filtered to remove the formed dicyclohexylurea and the filtrate is diluted with ethyl acetate to give a fine solid which is collected by filtration to give the crude product.
  • the resulting crude protected nonapeptide ethylamide is purified by a column of silica gel (solvent system, ethyl acetate:Pyridine:acetic acid:H 2 O, 60:20:6:10). The fractions which contain the pure product (checked by thin layer chromatography) were combined and evaporated to give the solid.
  • the solid (250 mg) is treated with 5 ml of hydrogen fluoride in the presence of anisole (0.1 ml) and 2-mercaptoethanol (0.1 ml) at 0° C. for 60 minutes and the hydrogen fluoride is removed in vacuo.
  • the residue is dissolved in 20 ml of water and passed through a column of Amberlite CG-140 (acetate form, 1 ⁇ 10 cm) and the column is washed well with water.
  • Amino acid analysis His, 0.96; Arg, 1.01; Trp, 1.89; Glu, 0.92; Ser, 0.96; Pro, 1.11; Ala, 1.00; Leu, 1.02; Tyr, 1.05 (86% recovery).

Abstract

The novel nonapeptide amide derivatives of the formula
(Pyr)Glu--R.sub.1 --Trp--Ser--R.sub.2 --(D)--Ala--R.sub.3
--Arg--Pro--NH--R4
wherein R1 is His, Tyr, Trp or p-NH2 --Phe; R2 is Tyr or Phe; R3 is Leu, Ile or Nle and R4 is alkyl of 1 to 3 carbon atoms which may be substituted with hydroxyl group have a strong ovulation inducing activity.

Description

This application is a continuation of application Ser. No. 491,482, filed July 24, 1974 (now abandoned).
The present invention relates to novel nonapeptide amide derivatives having strong ovulation inducing activity, which are represented by the formula:
(Pyr)Glu--R.sub.1 --Trp--Ser--R.sub.2 --(D)--Ala--R.sub.3 --Arg--Pro--NH--R.sub.4                                   (I)
wherein R1 is His, Tyr, Trp or p-NH2 --Phe; R2 is Tyr or Phe; R3 is Leu, Ile or Nle and R4 is alkyl of 1 to 3 carbon atoms which may be substituted with hydroxyl group.
The present invention relates also to a method for producing the nonapeptide amide derivatives (I).
In the present specification and the claims, amino acids and peptides are designated by abbreviations which are in common usage in the particular field of art or which have been approved by Committee on Biochemical Nomenclature of IUPAC-IUB. Amino acid is in the L-configuration unless otherwise designated.
The following abbreviations are used, for instance.
Ala: Alanine
Arg: Arginine
BOC: t-Butoxycarbonyl
Bzl: Benzyl
DCC: N,N'-dicyclohexylcarbodiimide
His: Histidine
HONB: N-hydroxy-5-norbornene-2,3-dicarboximide
HOSu: N-hydroxysuccinimide
IBOC: Isobornyloxycarbonyl
Ile: Isoleucine
Leu: Leucine
Nle: Norleucine
OMe: Methyl ester
OBzl: Benzyl ester
ONB: N-hydroxy-5-norbornene-2,3-dicarboxiimide ester
OSu: N-hydroxysuccinimide ester
Phe: Phenylalanine
p.NH2 --Phe: p-Aminophenylalanine
Pro: Proline
(Pyr)Glu: Pyroglutamic acid
Ser: Serine
Tos: Tosyl
Trp: Tryptophan
Tyr: Tyrosine
Z: Benzyloxycarbonyl
Referring to the above substituent R4, the straight or branched alkyl group of 1 to 3 carbon atoms which may be substituted with hydroxyl group is exemplified by methyl, ethyl, n-propyl, i-propyl, hydroxy-methyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-n-propyl, 3-hydroxy-n-propyl, 2,2-dihydroxy-i-propyl or the like.
It was known for many years that the hypothalamus contains factors which, at a higher level, control the secretion of tropic hormones from the pituitary. Recently, subsequent to the isolation of a thyrotropin-releasing hormone (TRH), a hormone which promotes the secretion of luteinizing hormone has been extracted in pure form from pigs and sheep and shown to be a decapeptide of the structure: H--(Pyr)Glu--His--Trp--Ser--Tyr--Gly--Leu--Arg--Pro--Gly--NH2. [A. V. Schally et al, Biochem. Biophys. Res. Commun., 43, 1334 (1971): R. Guillemin et al, Proc. Nat. Acad. Sci., U.S.A., 69, 278 (1972)]. This finding has been followed by the synthesis of a number of similar peptides and biological tests have also been performed on these analogous peptides. However, even a minor modification in the above amino acid composition diminishes seriously the physiological activity of the peptide and the above chemical structure has been considered to be essential to the genesis of maximal physiological activity. [A. V. Schally et al, Biochem. Biophys. Res. Commun., 48, 366 (1972)].
Under the circumstances, the present inventor has succeeded in synthesizing nonapeptide amide derivatives (I) and has surprisingly found that these compounds have more potent ovulation inducing activity than the naturally-occurring decapeptide. It has been also found by the present inventor that those compounds act upon the pituitary to promote the secretion of both luteinizing hormone and follicle-stimulating hormone. The present inventor further has found that those compounds are useful not only as drugs for human beings, e.g. drugs for diagnosis of the pituitary function or the gonadotropin deficiency and therapy of amenorrhea, but also as veterinary drugs particularly for the purpose of the animal breeding. The present invention is the culmination of those unexpected findings.
Therefore, it is the main object of the present invention to provide novel nonapeptide amide derivatives (I) which have strong ovulation inducing activity.
Another object of the present invention is to provide a method for the production of the nonapeptide amide derivatives (I).
Further objects of the present invention will be made clear in accordance with the description mentioned hereinafter in this specification.
The nonapeptide amide derivative (I) is produced by a method characterized by that a reagent (A)--L-pyroglutamic acid or a peptide fragment which has a L-pyroglutamic acid unit (i.e. H--(Pyr)Glu--) at its N-terminal end and at the same time which, from thereon, comprises the above amino acid sequence--is condensed with a reagent (B)--an amine component which corresponds to the balance of the nonapeptide amide derivative (I)--, said two reagents (A) and (B) being optionally protected by protecting group or groups, and then the protecting group or groups if any are removed.
Thus, the reagent (A) is L-pyroglutamic acid or a peptide fragment which has an L-pyroglutamic acid unit at its N-terminal end and at the same time which from thereon comprises amino acid sequence of formula (I), and the reagent (B) to be condensed with the reagent (A) is an amine component which corresponds to the balance of the nonapeptide amide derivative (I), the reagents (A) and (B) being optionally protected.
Basic combinations of the reagent (A) and the reagent (B) are exemplified in the following Table 1.
                                  TABLE 1                                 
__________________________________________________________________________
Combina-                                                                  
     Reagent                                                              
tion (A)              (B)                                                 
__________________________________________________________________________
1    (Pyr)Glu--OH     H--R.sub.1 --Trp--Ser--R.sub.2 --(D)-Ala--          
                      R.sub.3 --Arg--Pro--NH--R.sub.4                     
2    (Pyr)Glu--R.sub.1 --OH                                               
                      H--Trp--Ser--R.sub.2 --(D)-Ala--R.sub.3 --          
                      Arg--Pro--NH--R.sub.4                               
3    (Pyr)Glu--R.sub.1 --Trp--OH                                          
                      H--Ser--R.sub.2 --(D)-Ala--R.sub.3 --Arg--          
                      Pro--NH--R.sub.4                                    
4    (Pyr)Glu--R.sub.1 --Trp--Ser--OH                                     
                      H--R.sub.2 --(D)-Ala--R.sub.3 --Arg--Pro--          
                      NH--R.sub.4                                         
5    (Pyr)Glu--R.sub.1 --Trp--Ser--                                       
                      H--(D)-Ala--R.sub.3 --Arg--Pro--NH--R.sub.4         
     R.sub.2 --OH                                                         
6    (Pyr)Glu--R.sub.1 --Trp--Ser--                                       
                      H--R.sub.3 --Arg--Pro--NH--R.sub.4                  
     R.sub.2 --(D)-Ala--OH                                                
7    (Pyr)Glu--R.sub.1 --Trp--Ser--                                       
                      H--Arg--Pro--NH--R.sub.4                            
     R.sub.2 --(D)-Ala--R.sub.3 --OH                                      
8    (Pyr)Glu--R.sub.1 --Trp--Ser--                                       
                      H--Pro--NH--R.sub.4                                 
     R.sub.2 --(D)-Ala--R.sub.3 --Arg--OH                                 
9    (Pyr)Glu--R.sub.1 --Trp--Ser--                                       
                      NH.sub.2 --R.sub.4                                  
     R.sub.2 --(D)-Ala--R.sub.3 --Arg--Pro--                              
     OH                                                                   
__________________________________________________________________________
It has also been known that a protected L-glutamyl group shown by the general formula (II):
RCO--CH.sub.2 CH.sub.2 CH(NH.sub.2)CO--                    (II)
[wherein R is an alkoxy group (e.g. methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, etc.), an aralkyloxy group (e.g. benzyloxy, etc.) or amino] is easily converted to the L-pyroglutamyl group itself: ##STR1## by the contact with a base (e.g. ammonia, etc.) or an acid (e.g. acetic acid etc.) and that the group (II) is equivalent to L-pyroglutamyl group itself in this respect. In the method of the present invention, it is to be construed that the L-pyroglutamyl (i.e. H--(Pyr)Glu--) of the reagent (A) includes not only the L-pyroglutamyl group itself but also the protected L-glutamyl group of the formula (II). In case when H--(Pyr)Glu-- of the reagent (A) represents the group (II), the group (II) is easily converted to L-pyroglutamyl group itself in accordance with per se known means.
The condensation reaction according to this invention can be carried out by condensing means known for the formation of peptide linkages. Among such means of condensation are the azide process, chloride process, acid anhydride process, mixed acid anhydride process, DCC process, active ester process, Woodward reagent K process, carbodiimidazole process, oxidation-reduction process, DCC/HONB process and others [The Peptides, Vol. 1 (1966), Schroder and Lubke, Academic Press, New York, U.S.A. and Belgian Pat. No. 796,399].
Prior to the condensation reaction, one may protect the carboxyl and amino groups which should not be involved in the contemplated reaction or activate the carboxyl or/and amino groups which will take part in the reaction, by means which are known per se. The carboxyl groups in the starting material may be protected in the form of metal salts (e.g. sodium and potassium salts) or esters (e.g. methyl, ethyl, benzyl, p-nitrobenzyl, t-butyl or t-amyl esters).
Protective groups for amino groups in the starting materials may be any of conventional protecting groups of amino groups in peptide synthesis, e.g. benzyloxycarbonyl, t-butoxycarbonyl, isobornyloxycarbonyl, etc. The hydroxyl group of serine may be protected with a conventional protective group such as benzyl, t-butyl and other ether-forming groups. The hydroxyl group of tyrosine may be protected with benzyl, t-butyl and other ether-forming groups; the guanidino group of arginine may be protected with such groups as nitro, tosyl, carbobenzoxy, isobornyloxycarbonyl or adamantyloxycarbonyl. As examples of activated carboxyl groups in starting materials, there may be mentioned the corresponding acid anhydride, azide, active esters [esters with alcohols (e.g. pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethyl alcohol, p-nitrophenol, N-hydroxy-5-norbornene-2,3-dicarboximide, N-hydroxysuccinimide, N-hydroxyphthalimide or N-hydroxybenztriazole], etc. The activated amino groups in starting materials may for example be the corresponding phosphoric acid amide.
The following table shows some exemplary combinations of such forms of carboxyl and amino groups in materials (A) and (B).
              TABLE 2                                                     
______________________________________                                    
        Reagents                                                          
Exemplary (A)            (B)                                              
combinations                                                              
          COOH      NH.sub.2 COOH   NH.sub.2                              
______________________________________                                    
 1*       Free      Protected                                             
                             Protected                                    
                                    Free                                  
2         Activated Protected                                             
                             Free   Free                                  
3         Free      Protected                                             
                             Protected                                    
                                    Activated                             
______________________________________                                    
 (Note)                                                                   
 In the case designated by an asterisk *, a dehydrating agent (e.g. a     
 carbodiimide reagent such as dicyclohexylcarbodiimide) is preferably     
 present in the reaction system. A mode of practice of this invention may 
 be written as follows.                                                   
 ##STR2##
This reaction may be conducted in the presence of a solvent. The solvent can be selected from those known to be useful for peptide condensation reactions. Thus, anhydrous or aqueous dimethylformamide, dimethylsulfoxide, pyridine, chloroform, dioxane, dichloromethane, tetrahydrofuran and suitable mixtures of such solvents may be mentioned by way of example.
The reaction temperature is selected from within the range known to be employable for reactions leading to the formation of peptide bonds, i.e. normally within the range of about -20° C. to about 30° C. Further, the precursor materials (protected peptides) of the contemplated compounds according to this invention may also be easily prepared by solid-phase synthetic processes.
After the contemplated condensation reaction has been completed, if the product carries protective groups, they can be removed by routine procedures. Among such routine procedures are catalytic reduction in the presence of a catalyst such as palladium black, palladium-on-carbon, platinum or the like, hydrolysis by means of hydrogen fluoride, trifluoroacetic acid or the like, and reduction with metallic sodium in liquid ammonia.
The peptide (I) thus produced can be recovered from the reaction product mixture by procedures known for the recovery of peptides, e.g. by extraction, distribution, column chromatography, etc.
The peptide (I) may also be recovered in the form of a salt or metal complex compound.
As acids which are able to form salts with peptide (I), there may be mentioned inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, etc. and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranylic acid, cinnamic acid, naphthalenesulfonic acid or sulfanylic acid, for instance.
The metals which are able to form metal complex compounds with peptide (I) include, among others, zinc, nickel, cobalt, copper and iron. Such a metal complex compound can be produced by conventional procedures, for example, by reacting peptide (I) with the hydroxide or oxide of a metal of the above-mentioned variety at pH about 6 to 8.
The polypeptides (I) according to this invention have LH-RH (luteinizing hormone releasing hormone) activity and, accordingly, are able to promote the secretion of LH (luteinizing hormone) and FSH (follicle stimulating hormone). Therefore, polypeptides (I) are of use as drugs for promoting ovulations in women and other animals (e.g. rats, ewes, pigs, cows, mares, quails or hens). The peptides can also be used for other pharmaceutical purposes for which conventional LH-RH, LH and FSH preparations have been employed.
Since the LH-RH activity of polypeptides (I) is about 20 times that of known naturally-occurring LH-RH, their dosage may be determined for each application on the basis of the above multiple whilst other factors (e.g. the subject of administration of the kind of disease) are also taken into consideration. For example, a suitable dosage may be selected from within the range of about 2 ng. to 2 μg. daily per kilogram of body weight.
Polypeptides (I) are primarily administered non-orally (e.g. by injection or by the rectal or vaginal route), although they are orally administered in certain instances.
The dosage forms employable include, for example, injections, suppositories, pessaries and powders. The injections can be prepared by dissolving about 10γ to 100γ of polypeptide (I) in 1 ml. of physiological saline. Polypeptides (I) can be also made into lyophilized ampoule products with mannitol added as an excipient so that one may adminster them as injections for extemporaneous use.
The starting material peptides employable in the method of this invention can be prepared either by known processes for peptide synthesis or by utilizing such processes as found necessary.
RELATIVE OVULATION-INDUCING ACTIVITY OF THE PEPTIDE (I)
Ovulation-inducing activity is determined in Sprague-Dawley rats (4-day cycling female) in which the injection of the compound was made subcutaneously at 14:30 on the day of diestrous, and the ovulated ova in the ampilla of the oviduct were examined on the morning of the next day. The results (ED50) were compared with that (ED50) of LH-RH itself. The assay results on the object compounds are as follows.
______________________________________                                    
(Pyr)Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH.sub.2                     
(natural LH--RH)                                                          
Control                                                                   
       R.sub.1     R.sub.2                                                
                          R.sub.3                                         
                               R.sub.4  100%                              
______________________________________                                    
Peptide                                                                   
       His         Tyr    Leu  ethyl    6,100%                            
(I)    His         Tyr    Leu  n-propyl 4,800%                            
       His         Tyr    Leu  2-hydroxy-                                 
                                        4,300%                            
                               ethyl                                      
       His         Tyr    Leu  iso-propyl                                 
                                        3,600%                            
       His         Phe    Leu  ethyl    5,810%                            
       His         Phe    Leu  n-propyl 2,900%                            
       His         Tyr    Nle  ethyl    4,800%                            
       His         Phe    Ile  ethyl    3,200%                            
       Tyr         Tyr    Leu  ethyl    2,010%                            
       p-NH.sub.2 --Phe                                                   
                   Tyr    Leu  ethyl    2,150%                            
______________________________________                                    
For further illustration of the invention, examples are given as follows:
In those examples, the following abbreviations mean Rf value of a thin layer chromatography on silica gel with the following solvent system:
Rf1 : ethyl acetate:pyridine:acetic acid:water=60:20:6:10
Rf2 : n-butanol:ethyl acetate:acetic acid:water=1:1:1:1
Rf3 : n-butanol:acetic acid:water=4:1:1
Rf4 : chloroform:methanol:acetic acid=9:1:0.5
Explanations of the registered trade names used in the Examples are as follows:
Celite: Filter aid manufactured by Johns-Manville, U.S.A.
Biogel P-2: Materials for gel filtration manufactured by BIO.RAD, U.S.A.
Cephadex LH-20: Esterified dextran gel manufactured by Pharmacia Fine Chemicals, Sweden
Amberlite XAD-2: Polystyrene resin
Amberlite IRA-410: Strongly basic anion exchange resin
Amberlite CG-410: Strongly basic anion exchange resin
Amberlite CG-45: Weakly basic anion exchange resin
All these resins are manufactured by Rohm & Haas Co. Ltd. U.S.A.
EXAMPLE 1 Production of (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH2 --CH3 (a) Preparation of (Pyr)--Glu--His--Trp--Ser--Tyr--OH
In 100 ml. of methanol is dissolved 8.0 g. of Z--Ser--Tyr--OMe, and with the addition of 500 mg. of palladium black, catalytic reduction is performed at atmospheric temperature and pressure by introducing hydrogen gas in the solution of 4 hours. The catalyst is removed by filtration. The methanol is distilled off under reduced pressure at low temperature and the residue is dissolved in 30 ml. of dimethylformamide. To the solution are added 6.78 g. of crystals of (Pyr)Glu--His--Trp--OH, followed by cooling with ice. Thereafter, 5.4 g. of HONB and 5.0 g. of DCC are added and the entire mixture is stirred on an ice-bath for 8 hours and at room temperature for 10 hours.
The resultant byproduct dicyclohexylurea is filtered off and the filtrate is concentrated under reduced pressure. Following the addition of 100 ml. of ether, the precipitate formed is recovered by filtration, washed with ether and dried. Yield 12.2 g. This product is dissolved in a mixture of ethyl acetate-pyridine-acetic acid-water (60:20:6:10).
The solution is run onto a column (6.5 cm diameter×19 cm) of silica gel prepared with the same solvent mixture and the column is eluted with the same solvent mixture, whereupon contemplated (Pyr)Glu--His--Trp--Ser--Tyr--OMe emerges in the 1480 ml. to 1800 ml. fractions. This eluate is concentrated to dryness under reduced pressure and washed well with water. Yield 8.3 g. In thin-layer chromatography on silica gel, this product gives a single Pauly and Ehrlich-positive spot each at Rf1 =0.29, Rf2 =0.68, and Rf3 =0.43.
In 50 ml. of methanol is dissolved 7.2 g. of this product and, under cooling with ice, 30 ml, of 1N sodium hydroxide is slowly added to effect hydrolysis. The solution is stirred at room temperature for 3 hours. Then, following the addition of 30 ml. of 1N hydrochloric acid, the solution is cooled, whereupon a precipitate is formed. It is recovered by filtration, washed with cold water and dried. The product is dissolved in 5% aqueous ethanol and the solution is run onto a column (3 cm in diameter×25 cm) of Amberlite XAD-2. Elution is performed by the gradient method using 5% ethanol (800 ml.) and 90% ethanol (800 ml.). Fractions of the desired compound are pooled, concentrated under reduced pressure to remove the ethanol, and lyophilized. Yield 5.9 g. Rf1 =0.01, Rf2 =0.62, Rf3 =0.34.
Elemental analysis (for C34 H38 N8 O9.H2 O): Calcd.: C, 56.65; H, 5.59; N, 15.55. Found: C, 56.39; H, 5.70; N, 15.52.
Amino acid analysis (hydrolysis with 5.7N hydrochloric acid in the presence of thioglycolic acid): Glu, 1.05; His, 0.98; Trp, 0.95; Ser, 0.98; Tyr, 1.03
(b) Preparation of Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH3
In a mixture of 30 ml. of dioxane and 10 ml. of dimethylformamide, there are dissolved 1.14 g. of H--Leu--Arg(NO2)--Pro--NH--CH2 --CH3 and 447 mg. of Z--(D)--Ala--OH. To the solution is added 400 mg. of HONB and the mixture is cooled rapidly. Following the addition of 460 mg. of DCC, the mixture is stirred for 20 hours. The resultant by-product dicyclohexylurea is filtered off and the filtrate is concentrated to dryness under reduced pressure. The residue is dissolved in ethyl acetate under warming and the solution is washed with a 4% aqueous solution of sodium bicarbonate and, then, with water, followed by drying over anhydrous sodium sulfate and concentration to dryness under reduced pressure.
The residue is dissolved again in a small amount of ethyl acetate under heating and the solution is filtered to remove the small amounts of insolubles. The filtrate is allowed to stand, whereupon needles separate. These crystals are recovered by filtration, washed with ethyl acetate and dried. Yield 1.30 g. Melting point: 183°-184° C.;
[α]D 26 =-49.2° (c=0.5, methanol).
Elemental analysis, for C30 H47 O8 N9 : Calcd.: C, 54.45; H, 7.16; N, 19.05. Found: C, 54.42; H, 7.28; N, 18.86.
Rf1 =0.78, Rf2 =0.90, Rf4 =0.65.
(c) Preparation of (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH2 --CH3
In 20 ml. of acetic acid are dissolved 155 mg. of crystals of Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH3 and, following the addition of 100 mg. of palladium black, catalytic reduction is carried out at atmospheric temperature and pressure for 5 hours. The catalyst is filtered off, and following the addition of 0.45 ml. of 1N hydrochloric acid, the filtrate is concentrated to dryness under reduced pressure. The residue is dissolved in 10 ml. of water and lyophilized. The residual white fluffy product and 141 mg. of (Pyr)Glu--His--Trp--Ser--Tyr--OH are dissolved in 10 ml. of dimethylformamide, followed by the addition of 60 mg. of HONB. Under cooling with ice, 0.25 ml, of a 10% solution of N-ethyl-morpholine in dimethylformamide and, 50 mg. of DCC are added in this order. The mixture is stirred under cooling with ice for 5 hours and, then, at room temperature for 10 hours. The dimethylformamide is distilled off under reduced pressure and 20 ml. of water is added. The insolubles are filtered off and the filtrate is run onto a column (1 cm diameter×5 cm) of Amberlite IRA-410 (acetate form), which is then washed with 50 ml. of water. The effluent and washings are pooled and run onto a column (1.5 cm diameter×25 cm) of carboxymethyl-cellulose. Elution is carried out by the gradient method using 0.005M ammonium acetate (300 ml.) and 0.175M ammonium acetate (300 ml.). The 170 ml.- to 240 ml.-fractions are pooled and lyophilized, whereupon 208 mg. of white fluffy powder is obtained. Thin layer chromatography of this product shows evidence of an impurity having a large Rf value. Therefore, it is further purified by means of a column (2 cm diameter×20 cm) of Amberlite XAD-2. Thus, an aqueous solution of the above fluffy product is run onto a column of Amberlite XAD-2 prepared with water and elution is performed by the gradient method using water (250 ml.) and 75% ethanol (280 ml.). The 170 ml.- to 250 ml.-fractions are pooled and, after removal of the ethanol by distillation under reduced pressure, lyophilized. Yield 129 mg. Rf1 =0.062; Rf2 =0.358.
[α]D 26 =47.0° (c=0.5, 5% aqueous solution of acetic acid). Amino acid analysis (hydrolysis with HCl in thioglycolic acid): Glu, 0.98; His, 1.05; Trp, 1.04; Ser, 0.97; Tyr, 0.97; Ala, 1.00; Lue, 1.04; Arg, 1.03; Pro, 1.00; ethylamine, 1.02 (86% recovery).
Similarly, a polypeptide-amide of formula (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NHCH3 is obtained using, as one of the starting materials, Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH3 instead of Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH3 in the above (b). This product has the following physical and chemical properties.
[α]D 24 =-48.1° (c=0.6, 5% acetic acid).
Rf1 =0.055; Rf2 =0.335.
Amino acid analysis (hydrolysis with HCl in the presence of thioglycolic acid); Glu, 1.00; His, 1.02; Trp, 0.89; Ser, 0.90; Tyr, 0.98; Ala, 1.00; Lue, 1.00; Arg, 1.04; Pro, 1.02; methylamine, 0.97 (84.0% recovery).
EXAMPLE 2 Production of (Pyr)Glu--His--Trp--Ser--Tyr(D)--Ala--Leu--Arg--Pro--NH--CH2 --CH2 --CH3 (a) Preparation of Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH2 --CH3
In 2 ml. of 25% solution of hydrogen bromide in glacial acetic acid is dissolved 720 mg. of Z--Leu--Arg(NO2)--Pro--NH--CH2 --CH2 --CH3. The solution is shaken for 40 minutes, after which 20 ml. of dry ether is added. The resultant precipitate is recovered by filtration and washed with dry ether. The powder thus obtained is dried under reduced pressure over sodium hydroxide in a desiccator. The dried powder is dissolved in 5 ml. of dimethylformamide and, following the addition of 230 mg. of Z--(D)--Ala--OH and 200 mg. of HONB, the solution is cooled with ice and 1.5 ml. of a 10% solution of triethylamine in dimethylformamide is added. To this solution is added 230 mg. of DCC and the mixture is stirred at room temperature for 10 hours. Most of the dimethylformamide is distilled off under reduced pressure and the residue is dissolved by the addition of 50 ml. of ethyl acetate. The insolubles are filtered off and the filtrate is washed with a 4% aqueous solution of sodium bicarbonate three times and, then, with water twice. The solution is dried over anhydrous sodium sulfate and the ethyl acetate is distilled off. The residue is added to ether and the resultant powder is recovered by filtration.
It is dissolved in ethyl acetate under heating and purified by reprecipitation with ether.
The described procedure yields 723 mg. of powder.
[α]D 25 =-48.0° (c=1.0, methanol).
Elemental analysis, for C31 H48 O8 N9 : Calcd.: C, 55.18; H, 7.17; N, 18.68. Found: C, 54.89; H, 7.32; N, 18.44.
Rf4 =0.62.
(b) Preparation of (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH2 --CH2 --CH3
In a mixture of 10 ml. of acetic acid and 10 ml. of methanol, 150 mg. of the Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH2 --CH3 obtained according to the above (a) is catalytically reduced using palladium-on-carbon as the catalyst for 4 hours. The catalyst is filtered off and the solvent is distilled off from the filtrate under reduced pressure. The residue is dissolved in 0.4 ml. of a mixture of 1N hydrochloric acid and 10 ml. of water, and the solution is lyophilized. The procedure gives white fluffy powders.
This product and 141 mg. of (Pyr)Glu--His--Trp--Ser--Tyr--OH are dissolved in 10 ml. of dimethylformamide, followed by the addition of 60 mg. of HONB and 0.25 ml. of a 10% solution of N-ethylmorpholine in dimethylformamide. The mixture is cooled to -2° C. and 55 mg. of DCC is added. The mixture is stirred under cooling with ice for 5 hours and, then, at room temperature for 12 hours.
After the reaction has been completed, the dimethylformamide is distilled off under reduced pressure and the residue is dissolved in 20 ml. of water. The small amount of insolubles (dicyclohexyl-urea) is filtered off and the filtrate is run onto a column (1 cm diameter×4 cm) of Amberlite IRA-410 (acetate form), which is then washed with water. The effluent and washings are pooled and run onto a column (1.5 cm diameter×25 cm) of carboxymethylcellulose.
After washing with 0.005M ammonium acetate buffer, continuous elution is carried out using 300 ml. of 0.005M ammonium acetate buffer (pH 6.8) and 300 ml. of 0.2M ammonium acetate buffer (pH 6.9). The 160 ml.- to 230 ml.-fractions are pooled, lyophilized, rechromatographed under the same conditions as above, and lyophilized for a second time. The product is applied to a column (3 cm diameter×50 cm of Biogel P-2 (5% acetic acid as eluant) and the eluate containing the desired product is lyophilized. The described procedure gives 201 mg. of white fluffy powder.
[α]D 25 =-46.8° (c=0.5, 5% acetic acid).
Rf2 =0.37; Rf1 =0.08.
Amino acid analysis (hydrolysis with 5.7N hydrochloric acid in the presence of thioglycolic acid): His, 0.97; Arg, 0.97; Trp, 0.91; Ser, 0.91; Glu, 1.00; Pro, 1.00; Ala, 0.98; Lue, 0.97; Tyr, 0.94 (86.4% recovery.)
EXAMPLE 3 Production of (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH2 --CH2 --OH (a) Preparation of Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH2 --OH
In 3 ml. of 20% solution of hydrogen bromide in dioxane is dissolved 722 mg. of Z--Leu--Arg(NO2)--Pro--NH--CH2 --CH2 --OH. The solution is shaken for 60 minutes, after which 30 ml. of dry ether is added. The precipitate is recovered by decantation, washed with dry ether and dried well over sodium hydroxide in a desiccator under reduced pressure.
The product is dissolved in 5 ml. of dimethylformamide, followed by the addition of 230 mg. of Z--(D)--Ala--OH and 210 mg. of HONB. After cooling with ice, 0.16 ml. of triethylamine and, 230 mg. of DCC are added in this order. The mixture is stirred under cooling with ice for 1 hour and, then, at room temperature for 4 hours. The reaction mixture is filtered and the filtrate is added to 100 ml. of chloroform. The solution is washed with a 4% aqueous solution of sodium bicarbonate and, then, with water, dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure. The residue is dissolved in a solvent mixture of chloroform, methanol and acetic acid (9:1:0.5) and the solution is run onto a column (3 cm diameter×40 cm) of silica gel prepared with the same kind of the solvent as above, followed by development with the same kind of the solvent. The fractions giving an Rf4 value of 0.47 are pooled, concentrated to dryness under reduced pressure and washed with ether. The described procedure gives 640 mg. of powders.
[α]D 26 =-47.2° (c=0.5, methanol).
Elemental analysis, for C30 H47 O9 N9 : Calcd.: C, 53.16; H, 6.99; N, 18.60. Found: C, 52.84; H, 7.26; N, 18.21.
Rf4 =0.47.
(b) Preparation of (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH2 --CH2 --OH
In 10 ml. of acetic acid, 154 mg. of the Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH2 --OH is catalytically reduced using palladium black as the catalyst for 5 hours. The catalyst is filtered off and the filtrate is concentrated to dryness under reduced pressure. Following the addition of 10 ml. of water and 0.45 ml. of 1N hydrochloric acid, the concentrate is lyophilized. The powdery lyophilizate and 140 mg. of (Pyr)Glu--His--Trp--Ser--Tyr--OH are dissolved in 10 ml. of dimethylformamide, followed by the addition of 60 mg. of HONB and 0.25 ml. of a 10% solution of N-ethylmorpholine in dimethylformamide. The mixture is cooled to -2° C. and 60 mg. of DCC is added. The mixture is stirred under cooling with ice for 6 hours and, then, at room temperature for 12 hours. After the reaction has gone to completion, the dimethylformamide is distilled off under reduced pressure and the residue is dissolved in 10 ml. of water. The insolubles are filtered off and the filtrate is passed through a column (1 cm diameter×4 cm) of Amberlite IRA-410 (acetate form), whereby the product is converted to the acetate. Thereafter, the salt is purified by means of a column of carboxymethyl-cellulose and a column of Amberlite XAD-2 in the same manner as Example 1. After lyophilization, there are obtained white fluffy powder. Yield 146 mg.
[α]D 25 =-48.1° (c=0.5, 5% acetic acid).
Rf2 =0.31, Rf1 =0.025.
Amino acid analysis (hydrolysis with 5.7N hydrochloric acid in the presence of thioglycolic acid): His, 1.00; Arg, 0.98; Trp, 0.98; Ser, 0.92; Glu,1.00; Pro, 1.00; Ala, 0.99; Leu, 1.00; Tyr, 0.98 (87% recovery).
EXAMPLE 4 Production of (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH(CH3).sub.2 (a) Preparation of Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH(CH3)2
720 mg. of Z--Leu--Arg(NO2)--Pro--NH--CH(CH3)2 is treated in the same manner as Example 2-(a) and, then, condensed with Z--(D)--Ala--OH in a mixture of 5 ml. of dimethylformamide and 10 ml. of dichloromethane with the aid of DCC and HONB. The product is extracted with ethyl acetate to obtain 690 mg. of powders.
[α]D 25 =-48.3° (c=1.0, methanol).
Elemental analysis, for C31 H48 O8 N9 : Calcd.: C, 55.18; H, 7.17; N, 18.68. Found: C, 54.78; H, 7.09; N, 18.22.
Rf4 =0.61.
(b) Preparation of (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH(CH3).sub.2
By exactly the same procedure as that described in Example 2-(b), the above compound is prepared from Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH(CH3)2 and (Pyr)Glu--His--Trp--Ser--Tyr--OH. Yield 128 mg.
[α]D 25 =-47.5° (c=0.5, 5% acetic acid).
Rf2 =0.375, Rf1 =0.08.
Amino acid analysis (hydrolysis with 5.7N hydrochloric acid in the presence of thioglycolic acid): His, 0.99; Arg, 0.98; Trp, 0.89; Ser, 0.94; Glu, 1.00; Pro, 1.00; Ala, 1.00; Leu, 1.02; Tyr, 0.98 (86.5% recovery)
EXAMPLE 5 Production of (Pyr)Glu--His--Trp--Ser--Phe--(D)--Ala--Leu--Arg--Pro--NH--CH2 --CH3 (a) Preparation of (Pyr)Glu--His--Trp--Ser--Phe--OH
In 100 ml. of methanol are dissolved 4.0 g. of Z--Ser--Phe--OMe. The solution is subjected to a catalytic reduction with 500 mg. of palladium black at atmospheric pressure for 1.5 hours. The catalyst is removed by filtration and immediately the methanol is evaporated from the filtrate by distillation under reduced pressure and the residue is dissolved in 25 ml. of dimethylformamide. To the solution is added 4.1 g. of (Pyr)Glu--His--Trp--OH, followed by the addition of 3.8 g. of HONB and 3 g. of DCC at -5° C. The mixture is stirred at -5° C. for 2 hours, at 0° C. for 2 hours and at room temperature for 8 hours.
The resultant dicyclohexylurea is removed by filtration and the filtrate is concentrated to dryness under reduced pressure. The residue is triturated with ethyl acetate and the resultant powder is collected by filtration. Yield: 6.7 g. The powder is dissolved in 30 ml. of a mixture of methanol and chloroform (15:85) and the solution is run onto a column (6 cm diameter×12 cm) of silica gel prepared with a mixture of methanol and chloroform (15:85). The column is eluted with 600 ml. of a mixture of methanol and chloroform (15:85), 1 l. of a mixture of methanol and chloroform (25:75) and 1 l. of a mixture of methanol and chloroform (30:70). Fractions which is eluted with from 400 ml. of the mixture of methanol and chloroform (25:75) to 700 ml. of the mixture of methanol and chloroform (30:70) are pooled and concentrated to dryness under reduced pressure. The residue is triturated with ethyl acetate and the resultant powder is recovered by filtration to yield the compound [(Pyr)Glu--His--Trp--Ser--Phe--OMe]. Yield: 4.2 g. Rf1 =0.29.
In 20 ml. of methanol is suspended 3.5 g. of the compound which is produced just above and the suspension is cooled to 0° C., followed by the addition of 8 ml. of N sodium hydroxide solution. The mixture is stirred for one hour and neutralized with 8 ml. of N hydrochloric acid. The methanol is distilled off under reduced pressure and cold water is added to the residue. The resultant precipitates are collected by filtration, washed with cold water and dried to yield the object compound. Rf2 =0.61.
[α]D 26.5 =-3.3° (c=0.55, glacial acetic acid).
(b) Production of (Pyr)Glu--His--Trp--Ser--Phe--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH.sub.2 CH3
In 15 ml. of 25% solution of hydrogen bromide in glacial acetic acid is dissolved 1.6 g. of Z--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 CH3 and the solution is stirred at room temperature for 50 minutes. To the solution is added 150 ml. of dry ether and the resultant precipitates are collected by filtration, dried and dissolved in 30 ml. of water. The solution is run onto a column (2.5 cm diameter×15 cm) of Amberlite CG-410 (free base) and the column is washed well with a mixture of methanol and water (30:70). The effluent and the washing are combined and concentrated to evaporate the methanol. The residue is lyophilized to yield H--(D)--Ala--Leu--Arg(NO2)--Pro--NHCH2 CH3. Yield 1.2 g. Rf1 =0.21, Rf2 =0.64.
In 5 ml. of dimethylformamide are dissolved 225 mg. of the compound which is produced just above and 280 mg. of (Pyr)Glu--His--Trp--Ser--Phe--OH, followed by the addition of 150 mg. of HONB. The mixture is cooled to -10° C. and 90 mg. of DCC is added. The mixture is stirred at -10° C. for 2 hours, at 0° C. for 4 hours and at room temperature for 12 hours. The resultant mixture is filtered to remove the dicyclohexylurea and ethyl acetate is added to the filtrate. The resultant precipitates are collected by filtration, dried and dissolved in a mixture of ethanol and water (20:80) under heating. The solution is left standing to yield fine crystals and the crystals are collected by filtration. Yield 389 mg.
[α]D 26.5 =-43.6° (c=0.11, methanol) Rf1 =0.22, Rf2 =0.74.
(c) Production of (Pyr)Glu--His--Trp--Ser--Phe--(D)--Ala--Leu--Arg--Pro--NH--CH2 CH3
(I) In 10 ml. of 60% aqueous solution of formic acid is dissolved 150 mg. of the compound [H--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 CH3 ] which is produced as in the above (b), followed by the addition of 300 mg. of SnCl2.H2 O. The mixture is heated at 80° to 85° C. for 2.5 hours and concentrated to dryness under reduced pressure. The residue is extracted with 30 ml. of hot water of 80° C. and filtered. The filtrate is run onto a column (3 cm diameter×15 cm) of Amberlite XAD-2 (about 200 mesh).
The column is washed with water and subjected to a gradient elution with 300 ml. of water and 300 ml. of 100% ethanol. The object compound emerges in the 130 ml.- to 220 ml.-fractions, which are pooled and concentrated under reduced pressure to evaporate the ethanol. The residue is run onto a column (2 cm diameter×30 cm) of carboxymethyl-cellulose. The column is subjected to a gradient elution with ammonium acetate of from 0.005 to 0.2M (pH 6.8). The object compound emerges in 350 ml.- to 500 ml.-fractions, which are pooled and lyophilized to yield fluffy powder. Yield 112 mg.
[α]D 24 =-44.3° (c=0.53, in 5% acetic acid), Rf1 =0.088, Rf2 =0.73.
Amino acid analysis: His, 0.96; Arg, 1.04; Trp, 0.92; Ser, 0.96; Glu 0.99; Pro, 1.08; Ala 1,00; Leu, 1.00; Phe, 1.00; ethylamine 1.04 (85% recovery).
(II) In a mixture of 1 ml. of glacial acetic acid and 20 ml. of methanol dissolved 100 mg. of the compound which is produced by the procedure of the above (b), followed by the addition of 100 mg. of palladium black. The mixture is subjected to a catalytic reduction under atmospheric pressure for 2 days and subjected to filtration to remove the catalyst. The filtrate is concentrated to dryness under reduced pressure. The residue is dissolved in 3 ml. of 0.005M aqueous solution of ammonium acetate. The solution is run onto a column (2 cm diameter×30 cm) of carboxymethyl-cellulose and the column is subjected to a gradient elution under the same condition as in the above procedure (I). 350 ml.- to 460 -ml. fractions are pooled and lyophilized to yield the object compound, whose Rf value and specific rotation are identical with those of the compound produced in the above (I).
(III) In 5 ml. of anhydrous hydrogen fluoride containing 0.2 ml. of anisole and 0.1 ml. of mercaptoethanol are dissolved the compound which is produced by the procedure as in the above (b) and the mixture is stirred at 0° C. for 40 minutes. The mixture is concentrated to dryness under reduced pressure to evaporate the hydrogen fluoride. The residue is dissolved in 10 ml. of water and the insolubles are removed by filtration with Celite® (Registered trade name of the product produced by Johns-Manville, U.S.A.). The filtrate is passed through a column (1 cm diameter×10 cm) of Amberlite CG-410 (acetate form) and the column is washed with water. The effluent and the washings are combined and run onto a column (2 cm diameter×30 cm). The column is subjected to a gradient elution under the same condition as in the above (I). 340 ml.- to 460 ml.-fractions are pooled and lyophilized to yield the object compoud. Yield 42 mg.
The compound which is produced just above is identical in Rf value, specific rotation and ED50 value of ovulation inducing activity with the compound which is produced by the process of the above (I).
EXAMPLE 6 Production of (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Nle--Arg--Pro--NHCH2 CH3 (a) Production of Z--Nle--Arg(NO2)--Pro--NH--CH2 CH3
In 4 ml. of 25% solution of hydrogen bromide in glacial acetic acid is dissolved 477.5 mg. of Z--Arg(NO2)--Pro--NH--CH2 CH3 and the solution is stirred at room temperature for 30 minutes, followed by the addition of dry ether. The resultant precipitates are collected by filtration, washed with ether and dried over sodium hydroxide under reduced pressure.
On the other hand, 265.3 mg. of Z--Nle--OH is dissolved in a mixture of 2 ml. each of ethyl acetate and dioxane. While the solution is cooled to 0° C., 187 mg. of HONB and 226 mg. of DCC are added to the solution and the mixture is stirred for 3 hours.
The urea compound which is separated is removed by filtration. The filtrate is added to a solution of the above produced precipitates in 1 ml. of dimethylformamide, followed by the dropwise addition of 0.28 ml. of triethylamine. The mixture is stirred for 12 hours and subjected to distillation to evaporate the solvent. The residue is extracted with 100 ml. of chloroform. The extract is washed with 5% aqueous solution of sodium bicarbonate, water, 0.5N hydrochloric acid and water in this order and dried over anhydrous sodium sulfate. The chloroform is evaporated by distillation. The residue is triturated with ether and reprecipitated from ethanol with ether to yield the object compound. Yield 410 mg. Melting at 109°-111° C. (decomposition), [α]D 22 =-50.4° (c=0.5, ethanol).
Elemental analysis, (for C27 H42 O7 N8.1/2H2 O): Calcd.: C, 54.07; H, 7.22; N, 18.68. Found: C, 53.79; H, 7.09; N, 18.24.
(b) Production of Z--(D)--Ala--Nle--Arg(NO2)--Pro--NH--CH2 CH3
In 5 ml. of 25% solution of hydrogen bromide in glacial acetic acid is dissolved 200 mg. of Z--Nle--Arg(NO2)--Pro--NH--CH2 CH3 and the solution is stirred at room temperature for 40 minutes, followed by the addition of 50 ml. of dry ether. The resultant precipitates are collected by filtration, washed with ether and dried. The precipitates are run onto a column (1 cm diameter×5 cm) of Amberlite IRA-410 (free form) with 40% aqueous methanol as developer to remove the hydrogen bromide. The methanol is evaporated from the effluent by distillation and the residue is lyophilized to yield 120 mg. of powder. In a mixture of 20 ml. of dichloromethane and 5 ml. of dimethylformamide are dissolved the powder produced just above and 44.7 mg. of Z--(D)--Ala--OH. While cooling the solution to 0° C., 40 mg. of HONB and 46 mg. of DCC are added. The mixture is stirred at room temperature for 12 hours. The dicyclohexylurea which separates is removed by filtration and the filtrate is concentrated to dryness under reduced pressure. The residue is dissolved in 120 ml. of ethyl acetate. The solution is washed with 4% aqueous solution of sodium bicarbonate and water, and dried over anhydrous sodium sulfate and is concentrated to dryness under reduced pressure. The residue is dissolved in a little amount of ethanol and precipitated with ether and such precipitation is repeated to yield the object compound as powder. Yield 132 mg. [α]D 26 =-48.5° (c=0.5, methanol).
Elemental analysis, (for C30 H47 O8 N9): Calcd.: C, 54.45; H, 7.16; N, 19.05. Found: C, 54.48; H, 7.23; N, 18.72.
Rf1 =0.79, Rf2 =0.92, Rf4 =0.66.
(c) Production of (Pyr)Glu--His--Trp--Ser--Tyr--(D)--Ala--Nle--Arg--Pro--NHCH2 CH3
In 5 ml. of 25% solution of hydrogen bromide in glacial acetic acid is dissolved 100 mg. of Z--(D)--Ala--Nle--Arg(NO2)--Pro--NH--CH2 CH3 and the solution is stirred at room temperature for 50 minutes, followed by the addition of 40 ml. of dry ether. The resultant precipitates are collected by filtration, washed with ether and dried over sodium hydroxide under reduced pressure. The product is run onto a column of Amberlite CG-45 (free form) with 40% aqueous methanol to remove the hydrogen bromide. The methanol is removed from the effluent by distillation under reduced pressure and the residue is lyophilized. The lyophilizate and 100 mg. of (Pyr)Glu--His--Trp--Ser--Tyr--OH are dissolved in 4 ml. of dimethylformamide. After the addition of 45 mg. of HONB, the mixture is cooled to -5° to -7° C., followed by the addition of 40 mg. of DCC. The mixture is stirred under cooling with ice for 5 hours and at room temperature for 10 hours. The dimethylformamide is removed by evaporation and 30 ml. of ethyl aetate is added to the residue. The mixture is filtered and the filter cake is dried. The product is dissolved in 2 ml. of anhydrous hydrogen fluoride containing 0.05 ml. of anisole and 0.05 ml. of mercaptoethanol and the solution is stirred at 0° C. for 40 minutes. The hydrogen fluoride is removed by distillation under reduced pressure and the residue is dissolved in 10 ml. of water. The insolubles are removed by filtration and the filtrate is run onto a column (1 cm diameter×5 cm) of Amberlite IRA-410 (acetate form), whereby the product is converted to the acetate. The effluent is passed through a column (1.5 cm diameter×30 cm) of carboxymethylcellulose and the column is subjected to a gradient elution with 400 ml. of 0.005M ammonium acetate and 400 ml. of 0.2M ammonium acetate. 290 ml.- to 320 ml.-fractions which show the maximum absorption in the ultraviolet absorption spectrum are pooled and lyophilized to yield fluffy powder. Yield 105 mg. Rf1 =0.063, Rf2 =0.360, [α]D 26 =-46.0° (c=0.3, 5% aqueous acetic acid).
Amino acid analysis (hydrolysis with 5.7N hydrochloric acid in the presence of thioglycolic acid).
Glu, 1.10; His, 1.02; Trp. 0.91; Ser, 0.98; Tyr, 1.00; Ala, 1.00; Nle, 1.02; Arg, 0.98; Pro, 0.97; ethylamine 1.04 (84% recovery)
EXAMPLE 7 Production of (Pyr)Glu--His--Trp--Ser--Phe--(D)--Ala--Ile--Arg--Pro--NHCH2 CH3
3 G. of BOC--Pro--resin (proline content: 0.314 millimol/g) is supplied to a reactor of peptide automatic synthesizer (APS-800 made by Shimidzu Seisakusho, Ltd., Japan) and swelled with dichloromethane for 12 hours and amino acids are introduced in the following cycle.
Dichloromethane (3 minutes×3 times)→50% trifluoroacetic acid/dichloromethane (10 minutes and 30 minutes, 2 times)→dichloromethane (3 minutes×3 times)→ethanol (3 minutes×3 times)→dichloromethane (3 minutes×3 times)→10% triethylamine/chloroform (10 minutes)→chloroform (3 minutes×3 times)→dichloromethane (3 minutes×2 times)→BOC-amino acid→anhydride (produced by conventional method from BOC-amino acid and DCC) (30 minutes and 60 minutes, 2 times)→acetylation (dichloromethane, triethylamine and acetic anhydride) (1 hour) dichloromethane (3 minutes×3 times) [Only (Pyr)--Glu--OH is used as it is without BOC-group and the condensation reaction is carried out in dimethylformamide with DCC].
Finally the resin is washed with ethanol, chloroform, dimethylformamide and ether in the order mentioned, and dried. Yield 4.12 g. The following BOC-amino acids are employed.
BOC--Arg(Tos), BOC--Ile, BOC--(D)--Ala, BOC--Phe, BOC--Ser (Bzl), BOC--Trp, BOC--His(Tos).
3 Grams of the resin which is produced as above is suspended in 20 ml. of dimethylformamide and the solution is saturated with ethylamine at 20° C. The mixture is stirred at room temperature for 40 hours. The resin is removed by filtration and the filtrate is concentrated to dryness under reduced pressure. The residue is triturated with ether to yield powder of crude (Pyr)Glu--His(Tos)--Trp--Ser(Bzl)--Phe--(D)--Ala--Ile--Arg(Tos)--Pro--NH--CH2 CH3. Yield 720 mg. The powder is dissolved in a mixture of ethyl acetate, pyridine, acetic acid and water (60:20:6:10) and the solution is run onto a column (3 cm diameter×20 cm) of silica gel which is prepared with the same kind of the solvent mixture. The column is eluted with the same kind of the solvent mixture. Fractions showing Rf value of 0.4 on thin layer chromatography on silica gel with methanol-chloroform (15:85) are pooled and concentrated to dryness under reduced pressure. The residue is triturated with ethyl acetate and the resultant powder is collected by filtration. Yield 240 mg. The powder is dissolved in 5 ml. of hydrogen fluoride containing 0.05 ml. of thioglycolic acid and 0.2 ml. of anisole and the solution is stirred at 0° C. for one hour. The hydrogen fluoride is removed by evaporation and the residue is dissolved in 10 ml. of water. The solution is run onto a column (1 cm diameter×10 cm) of Amberlite IRA-410 (acetate form). The effluent is purified by passing through a column (2 cm diameter×10 cm) of Amberlite XAD-2 twice, a column (1.9 cm diameter×25 cm) of carboxymethyl-cellulose twice and a column (1 cm diameter×60 cm) of Cephadex LH-20 once, and finally lyophilized to yield fluffy powder. Yield 42 mg. Rf1 =0.071, Rf2 =0.37.
Amino acid analysis (hydrolysis with hydrochloric acid in the presence of thioglycolic acid)
Glu, 1.01; His, 0.93; Trp, 0.92; Ser, 0.99; Phe, 1.00; Ala, 1.03; Ile, 0.98; Arg, 1.00; Pro, 1.08; ethylamine 1.04 (88% recovery)
EXAMPLE 8 Production of (Pry)Glu--Tyr--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NHCH2 CH3 (a) Preparation of BOC--Tyr--(OBzl)--(D)--Ala--OBzl
In 100 ml. of acetonitrile are dissolved 11.1 g. of BOC--Tyr--(OBzl)--OH and 10.9 g. of (D)--Ala--OBzl-p-toluene-sulfonate. The solution is cooled to 0° C. and 6.8 g. of DCC, 4.5 g. of HONB and 4.34 ml. of triethylamine are added. The mixture is stirred at room temperature for 19 hours, after which the precipitated urea compound is filtered off. The filtrate is distilled and the residue is extracted with 200 ml. of ethyl acetate. The extract is washed with a 5% aqueous solution of sodium hydrogen carbonate, 0.1N hydrochloric acid and water in the order mentioned and dried over Na2 SO4. The ethyl acetate is distilled off and the residue is crystallized from petroleum ether and, then, recrystallized from ethyl acetate-petroleum ether. Yield 13.5 g. Melting point: 113°-114° C.; [α]D 21 =+18.4° (c=1, methanol), Rf4 =0.76.
Elemental analysis, for C31 H36 O6 N2 : Calcd.: C, 69.90; H, 6.81; N, 5.26%. Found: C, 69.72; H, 6.75; N, 5.42%.
(b) Preparation of BOC--Ser--Tyr--(OBzl)--(D)--Ala--OBzl
In 100 ml. of trifluoroacetic acid is dissolved 11 g. of BOC--Tyr(OBzl)--(D)--Ala--OBzl. The solution is allowed to stand at room temperature for 30 minutes, after which time the solvent is distilled off under reduced pressure.
The residue is dried over sodium hydroxide under reduced pressure in a desiccator.
On the other hand, 4.1 g. of BOC--Ser and 4.0 g. of 2,4-dinitrophenol are dissolved in 50 ml. of tetrahydrofuran. This solution is cooled to 0° C. and, after the addition of 4.5 g. of DCC, stirred at 0° C. for 2 hours.
The precipitated dicyclohexylurea is filtered off, and the amine component (H--Tyr(OBzl)--(D)--Ala--OBzl) previously prepared is dissolved in the filtrate. The solution is cooled to 0° C. and 4.2 ml. of triethylamine is added dropwise. The solution is stirred at room temperature for 5 hours, after which the tetrahydrofuran is distilled off under reduced pressure.
The residue is dissolved in 200 ml. of ethyl acetate and the solution is washed with a 5% aqueous solution of sodium hydrogen carbonate, 0.1N hydrochloric acid and water in the order mentioned, followed by drying over Na2 SO4. The ethyl acetate is distilled off and the residue is crystallized from petroleum ether and, then, recrystallized from ethyl acetate-petroleum ether. Yield 9.7 g.
Rf4 =0.57; [α]D 21 =-4.1° (c=1, methanol); Melting point: 124°-125° C.
Elemental analysis, for C34 H41 O8 N3 : Calcd.: C, 65.89; H, 6.67; N, 6.78%. Found: C, 65.82; H, 6.59; N, 6.50%.
(c) Preparation of BOC--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NHCH2 CH3
In 100 ml. of methanol is dissolved 2.16 g. of BOC--Ser--Tyr(OBzl)--(D)--Ala--OBzl and, in the presence of palladium black, catalytic reduction is carried out for 4 hours, after which time the catalyst is filtered off. The methanol is distilled off and the residue is dissolved in 10 ml. of dimethylformamide. In this solution are dissolved 1.6 g. of H--Leu--Arg(NO2)--Pro--NHCH2 CH3 and 690 mg. of HONB. After the solution is cooled to 0° C., 795 mg. of DCC is added with stirring. The mixture is stirred at 0° C. for 2 hours and, then, at room temperature for 5 hours. The precipitated urea compound is filtered off and the dimethylformamide is removed by distillation under reduced pressure. The residue is extracted with 50 ml. of n-butanol and washed with a 5% aqueous solution of sodium hydrogen carbonate, 0.1N hydrochloric acid and water in the order mentioned. The n-butanol is distilled off and the residue is solidified with ether and precipitated from ethanol-ether. Yield 2.25 g. Rf4 =0.30; Melting point: 149°-151° C. (decomp.); [ α]D 27 =-26.6° (c=1, methanol).
Elemental analysis, for C39 H63 O12 N11.3/2H2 O: Calcd.: C, 51.75; H, 7.35; N, 17.02%. Found: C, 51.89; H, 7.30; N, 16.72%.
(d) Preparation of Z--Tyr(Z)--Trp--OBzl
In a solvent mixture of dioxane-ethyl acetate (50 ml.-10 ml.) are dissolved 9.0 g. of Z--Tyr--(Z)--OH and 10.2 g. of Trp--OBzl-p-toluenesulfonate. The solution is cooled to 0° C. and 3.93 g. of HONB, 4.53 g. of DCC and 3.0 ml. of triethylamine are added. The mixture is stirred for 5 hours, after which the precipitated urea compound is filtered off. The solvent is removed by distillation under reduced pressure and the residue is extracted with 200 ml. of ethyl acetate. The extract is washed with a 5% aqueous solution of sodium hydrogen carbonate, 1N hydrochloric acid and water in the order mentioned, followed by drying over Na2 SO4. The ethyl acetate is distilled off and the residue is crystallized from petroleum ether and recrystallized from ethyl acetate-petroleum ether. Yield 13 g. Rf4 =0.88; Melting point: 103°-104° C.; [α]D 23 =-4.7° (c=1, methanol).
Elemental analysis, for C43 H39 O8 N3 : Calcd.: C, 71.16; H, 5.42; N, 5.79%. Found: C, 71.11; H, 5.29; N, 5.76%.
(e) Preparation of Z--(Pyr)Glu--Tyr--Trp
In 100 ml. of methanol is dissolved 5.8 g. of Z--Try(Z)Trp--OBzl and, in the presence of palladium black, catalytic reduction is carried out for 5 hours. After the catalyst is filtered off, the methanol is removed by distillation under reduced pressure. The residue is dissolved in 20 ml. of dimethylformamide, and 3.39 g. of Z--(Pyr)Glu--ONB and 1.12 ml. of triethylamine are added. The mixture is stirred at room temperature for 12 hours, after which the dimethylformamide is distilled off. To the residue are added 100 ml. of ethyl acetate and 100 ml. of water. The water layer is rendered acidic with 1N hydrochloric acid and extracted with 100 ml. of n-butanol. The extract is washed with water and the n-butanol is distilled off. The residue is triturated with ether to yield powder. This is reprecipitated from ethanol-ether. Yield 4.5 g. Rf1 =0.63; Melting point: 165°-169° C. (decomp.); [α]D 21 =-4.8° (c=0.5 in methanol).
Elemental analysis, for C33 H32 O8 N4.H2 O: Calcd.: C, 62.85; H, 5.43; N, 8.89%. Found: C, 62.96; H, 5.35; N, 8.76%.
(f) Preparation of (Pyr)Glu--Tyr--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NHCH2 CH3
In 20 ml. of methanol is dissolved 184 mg. of Z--(Pyr)Glu--Tyr--Trp and, in the presence of palladium black, hydrogenation is carried out for 3 hours. After the catalyst has been filtered off, the methanol is distilled off under reduced pressure and the residue is dissolved in 2 ml. of dimethylformamide. On the other hand, 316 mg. of BOC--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NHCH2 CH3 is treated with 10 ml. of trifluoroacetic acid in the presence of 0.36 ml. of 1N hydrochloric acid for 40 minutes. The trifluoroacetic acid is distilled off and the residue is triturated with ether and thoroughly dried over sodium hydroxide in a desiccator. This powder and 81 mg. of HONB are dissolved in the previously prepared dimethylformamide solution, followed by cooling to -2° C. Then, 93 mg. of DCC and 0.05 ml. of N-ethylmorpholine are added and the resultant mixture is stirred at 0° C. for 2 hours and, then, at room temperature overnight. The precipitated urea compound is filtered off and 50 ml. of ether is added to the filtrate. The precipitate is recovered by filtration. Yield 350 mg. This product is passed over 7 g. of silica gel using the developer solvent mixture of Rf1. The fractions rich in the desired compound are pooled and the solvent is distilled off. The residue is triturated with ethyl acetate. Yield 270 mg. A 150 mg. portion of this product is treated with 4 ml. of anhydrous hydrogen fluoride in the presence of 0.1 ml. of anisole and 0.1 ml. of 2-mercaptoethanol at 0° C. for 1 hour, after which the hydrogen fluoride is distilled off under reduced pressure. The residue is dried over sodium hydroxide in a desiccator. The residue is extracted with 50 ml. of water and the extract is run onto a column (1 cm diameter×5 cm) of Amberlite IRA-410 (acetate form). The effluent and aqueous washings are pooled and run onto a column (1.5 cm diameter×19 cm) of carboxymethyl-cellulose. Elution is carried out by the linear gradient method using 0.005N ammonium acetate (280 ml.) to 0.15N ammonium acetate (280 ml.). The 110 ml.- to 210 ml.-fractions are pooled and lyophilized to obtain 95 mg. of the contemplated product. Rf1 =0.35; [α]D.sup. 24 =-39.0° (c=0.5, 5% acetic acid); amino acid analysis (hydrolysis with 5.7N HCl in the presence of 4% thioglycolic acid at 110° C.); Arg, 1.07; Trp, 1.03; Ser, 0.89; Glu, 1.00; Pro, 1.00; Ala, 1.00; Leu, 1.00; Tyr, 2.00; ethylamine, 1.05. (81% recovery).
EXAMPLE 9 Production of (Pyr)Glu--p--NH2 --Phe--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH2 --CH3 (a) Preparation of BOC--p--NO2 --Phe--OH
In a mixture of 40 ml. of 1N aqueous solution of sodium hydroxide and 150 ml. of dimethylformamide are dissolved 6.3 g. of p--NO2 --Phe--OH and 13.3 g. of t-butylpentachlorophenyl carbonate. Following the addition of 5 ml. of triethylamine, the solution is reacted at room temperature for 48 hours. The solvent is distilled off and the residue is dissolved in water, followed by extraction with ether. The water layer is adjusted to pH 3 with citric acid and extracted with ethyl acetate. The organic layer is dried over anhydrous magnesium sulfate and the solvent is distilled off. The residue is triturated with petroleum ether and recovered by filtration. The product is purified by column chromatography on silica gel and the fractions containing the desired product is pooled and distilled to remove the solvent. The residue is crystallized from ether-petroleum ether. Yield 3.8 g. Melting point: 103°-104° C.; [α]D 24 =-32.0° (c=0.75, dimethylformamide); Rf4 =0.61.
Elemental analysis, (for C14 H18 O6 N2): Calcd.: C, 54.19; H, 5.85; N, 9.03%. Found: C, 54.21; H, 5.86; N, 9.21%.
(b) Preparation of BOC--p--NH2 --Phe--OH
In 80 ml. of methanol is dissolved 2.0 g. of BOC--p--NO2 --Phe--OH and, using palladium black as the catalyst, catalytic reduction is carried out at room temperature for 8 hours. The catalyst is removed by filtration and the solvent is distilled off. The residue is triturated with petroleum ether and recovered by filtration. The product is further recrystallized from ethyl acetate-petroleum ether. Yield 1.5 g. Melting point: 121° C.; [α]D 24 =-2.2° (c=1.0, dimethylformamide); Rf4 =0.40.
Elemental analysis, (for C14 H20 O4 N2): Calcd.: C, 59.98; H, 7.19; N, 9.99%. Found: C, 59.47; H, 7.20; N, 9.71%.
(c) Preparation of BOC--p--NH--Z--Phe
In 20 ml. of a 1N aqueous solution of sodium hydrogen carbonate is dissolved 1.5 g. of BOC--p--NH2 --Phe--OH. With vigorous stirring under cooling with ice, 1.1 g. of benzyloxycarbonyl chloride is added. In the course of reaction 30 ml. of water is further added and the reaction is conducted for 3 hours. Thereafter, 1N hydrochloric acid is added to the reaction mixture to adjust the pH to 2 and the resultant oily precipitate is extracted with ethyl acetate. The ethyl acetate layer is collected, washed with water and dried over anhydrous magnesium sulfate. The solvent is distilled off and the residue is triturated with petroleum ether to obtain a crude product. This product is recrystallized from ether-petroleum ether. Yield 1.84 g.; Melting point: 156°-157° C.; [α]D 24 =-3.34° (c=0.7, dimethylformamide); Rf4 =0.67.
Elemental analysis, (for C22 H26 O6 N2): Calcd.: C, 63.75; H, 6.32; N, 6.76%. Found: C, 63.76; H, 6.25; N, 6.86%.
(d) Preparation of BOC--Trp--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH3
In 5 ml. of dimethylformamide is dissolved 466 mg. of H--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH3. Following the addition of 370 mg. of BOC--Trp--ONB, the solution is reacted at room temperature for 3 hours. The solvent is distilled off and ethyl acetate is added to the residue. The resultant powder is recovered by filtration and boiled in ethyl acetate, followed by cooling and allowing it to stand. The precipitate is collected by filtration. Yield 590 mg. Melting point: 189°-190° C. (decomposition): [α]D 22 =-43.8° (c=0.6, dimethylformamide); Rf4 =0.32.
Elemental analysis, (for C50 H73 O13 N13.2H2 O): Calcd.: C, 54.58; H, 7.06; N, 16.55%. Found: C, 54.84; H, 6.90; N, 16.54%.
(e) Preparation of BOC--p--NH--Z--Phe--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--(NO2)--Pro--NH--CH2 --CH3
In the presence of mercaptoethanol, 560 mg. of BOC--Trp--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH3 is treated with 5 ml. of trifluoroacetic acid at room temperature for 30 minutes, after which time ether is added. The resultant precipitate is recovered by filtration and dried over sodium hydroxide in a desiccator.
The product is dissolved in 5 ml. of dimethylformamide and the solution is neutralized with 0.1 ml. of N-ethylmorpholine.
To this solution is added a dimethylformamide solution of BOC--p--NH--Z--Phe--ONB which has been prepared from 217 mg. of BOC--p--NH--Z--Phe and 145 mg. of HONB by the DCC process. The mixture is reacted at room temperature for 12 hours, after which time the solvent is distilled off. To the residue is added ethyl acetate and the resultant solid is recovered by filtration. Yield 518 mg. Melting point: 119°-120° C. (decomposition); [α]D 22 =-29.7° (c=0.6, dimethylformamide); Rf4 =0.37.
Elemental analysis, (for C67 H89 O15 N15.2H2 O): Calcd.: C, 58.29; H, 6.65; N, 15.22%. Found: C, 58.18; H, 6.69; N, 14.81%.
(f) Preparation of (Pyr)Glu--p--NH2 --Phe--Trp--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH3
In the presence of mercaptoethanol, 470 mg. of BOC--p--NH2 --Z--Phe--Trp--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 --CH3 is treated at room temperature for 30 minutes, after which ether is added. The resultnt precipitate is recovered by filtration and dried over sodium hydroxide in a desiccator. The product is dissolved in 6 ml. of dimethylformamide and the solution is neutralized with 0.045 ml. of N-ethylmorpholine. Following the addition of 185 mg. of IBOC--(Pyr)--Glu--OSu, the solution is reacted at room temperature for 48 hours. The solvent is distilled off and the residue is triturated with ethyl acetate. The resultant powder is recovered by filtration. The described procedure gives 425 mg. of ##STR3## A 375 mg. portion of this product is treated with 5 ml. of anhydrous hydrogen fluoride in the presence of mercaptoethanol and anisole at 0° C. for 1 hour. After removal of the hydrogen fluoride by distillation, the residue is dissolved in water and extracted with ether. The water solution is passed columnwise over Amberlite IR-410 (acetate form, 0.9 cm diameter×15 cm) and the effluent and aqueous washings are pooled and lyophilized. The product is dissolved in 0.005M ammonium acetate buffer and run onto a column (1.8 cm diameter×19 cm) of carboxymethyl-cellulose. Elution is carried out by the linear gradient method using 0.005M (300 ml.) to 0.2M (300 ml.) ammonium acetate buffer and the 90 ml.- to 140 ml.-fractions are pooled and lyophilized. Yield 170 mg.
[α]D 22 =-41.8° (c=0.56, 5% acetic acid); Rf1 =0.16.
Elemental analysis, (for C58 H78 O12 N15.3CH3 COOH.4H2 O): Calcd.: C, 53.77; H, 6.91; N, 14.70%. Found: C, 54.09; H, 6.58; N, 14.84%.
Amino acid analysis (hydrolysis with 5.7N hydrochloric acid in the presence of 4% thioglycolic acid at 110° C. for 24 hours):
Arg, 0.97; Trp, 0.84; p--NH2 --Phe, 0.97; Ser, 1.00; Glu, 1.00; Pro, 0.99; Ala, 1.02; Leu, 1.02; Tyr, 1.08; ethylamine, 1.00.
EXAMPLE 10 Production of (Pyr)Glu--Trp--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH2 CH3 (a) Preparation of Z--(Pyr)Glu--Trp--OBzl
To a solution of Z--(Pyr)Glu--ONB (1.7 g) and H--trp--OBzl p-toluenesulfonate (2.1 g) in acetonitrile (50 ml) was added triethylamine (0.61 ml), and the mixture is stirred for 12 hours at room temperature. The reaction mixture is evaporated in vacuo to dryness. The residue is dissolved in ethyl acetate (100 ml), washed with 1N HCl and 5% aqueous NaHCO3, dried over anhydrous Na2 SO4 and evaporated to dryness. The residue is crystallized from petroleum ether and recrystallized from ethyl acetate-petroleum ether: yield 1.7 g; melting point 129°-130° C.; [α]D 25 =+3.1° (c=1.0 in dimethylformamide); Rf4 =0.42.
Elemental analysis, for C31 H29 O6 N3 : Calcd.: C, 69.00; H, 5.42; N, 7.79%. Found: C, 68.85; H, 5.48; N, 7.53%.
(b) Preparation of BOC--Trp--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 CH3
BOC--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 CH3 (670 mg) is treated with trifluoroacetic acid (10 ml) at room temperature for 20 minutes, and to this solution is added dry ether (50 ml) to yield a fine solid which is dried over NaOH-pellets in vacuo. The resulting powder is dissolved in dimethylformamide (5 ml) and to this solution is added triethylamine (0.11 ml) together with BOC--Trp--ONB which is prepared from BOC--Trp--OH (243 mg) and HONB (150 mg) by the DCC method. The mixture is stirred for 12 hours at room temperature and the resulting product is precipitated by addition of ethyl acetate (50 ml). The precipitate is collected by filtration and washed with water. The resulting precipitate is purified by reprecipitation from dimethylformamide-ethyl acetate: yield 720 mg; melting point 190°-193° C.; [α]D 25 =-42.4° (c=0.5 in dimethylformamide); Rf4 =0.27.
Elemental analysis, for C50 H73 O13 N13 H2 O: Calcd.: C, 55.49; H, 6.98; N, 16.82%. Found: C, 55.14; H, 7.16; N, 16.76%.
(c) Preparation of (Pyr)Glu--Trp--Trp--Ser--Tyr--(D)--Ala--Leu--Arg--Pro--NH--CH2 CH3
Z--(Pyr)Glu--Trp--OBzl obtained above (215 mg) is dissolved in methanol (50 ml) and then hydrogenated over palladium-black as a catalyst for 3 hours. The solution is filtered to remove the catalyst and evaporated to dryness. The residue is washed with ether and collected by filtration to give the corresponding free acid.
BOC--Trp--Ser--Tyr--(D)--Ala--Leu--Arg(NO2)--Pro--NH--CH2 CH3 (426 mg) is treated with trifluoroacetic acid (5 ml) in the presence of 2-mercaptoethanol (0.1 ml) and N--HCL (0.4 ml) at room temperature for 30 minutes, and to this solution is added dry ether to give a fine white solid which is collected by filtration and dried over NaOH-pellets in vacuo to give the corresponding free base.
The powder obtained is dissolved in dimethylformamide (2 ml) together with N-ethylmorpholine (0.06 ml), and to this are added the above described free acid and HONB (102 mg). The mixture is cooled to 0° C. and to this is added DCC (110 mg). The solution is stirred for 2 hours at 0° and for additional 10 hours at room temperature. The reaction mixture is filtered to remove the formed dicyclohexylurea and the filtrate is diluted with ethyl acetate to give a fine solid which is collected by filtration to give the crude product. The resulting crude protected nonapeptide ethylamide is purified by a column of silica gel (solvent system, ethyl acetate:Pyridine:acetic acid:H2 O, 60:20:6:10). The fractions which contain the pure product (checked by thin layer chromatography) were combined and evaporated to give the solid. The solid (250 mg) is treated with 5 ml of hydrogen fluoride in the presence of anisole (0.1 ml) and 2-mercaptoethanol (0.1 ml) at 0° C. for 60 minutes and the hydrogen fluoride is removed in vacuo. The residue is dissolved in 20 ml of water and passed through a column of Amberlite CG-140 (acetate form, 1×10 cm) and the column is washed well with water. The eluate and washings are combined and subjected to a chromatography on a carboxymethylcellulose column (1.2 diameter×30 cm) with a gradient elution method (pH 6.8, ammonium acetate buffer, 0.005M/0.15 M=300 ml/300 ml). The pure peptide is eluated in 160-260 ml fractions which are combined and lyophilized to a constant weight: yield 100 mg; [α]D 25 =-47.2° (c=0.25 in 5% acetic acid).
Rf1 =0.31, Rf2 =0.76. Amino acid analysis: His, 0.96; Arg, 1.01; Trp, 1.89; Glu, 0.92; Ser, 0.96; Pro, 1.11; Ala, 1.00; Leu, 1.02; Tyr, 1.05 (86% recovery).

Claims (18)

What is claimed:
1. A compound of the formula
(Pyr)Glu--R.sub.1 --Trp--Ser--R.sub.2 --(D)--Ala--R.sub.3 --Arg--Pro--NH--R.sub.4
wherein R1 is His, Tyr, or p--NH2 --Phe, R2 is Tyr or Phe, R3 is Leu, Ile or Nle and R4 is alkyl of 1 to 3 carbon atoms which may be substituted therefor, by hydroxy.
2. A compound as claimed in claim 1, wherein R1 is His.
3. The compound as claimed in claim 1, wherein R1 is Tyr or p--NH2 --Phe.
4. The compound as claimed in claim 1, wherein R2 is Tyr.
5. A compound as claimed in claim 1, wherein R3 is Leu.
6. The compound as claimed in claim 1, wherein R1 is His, R2 is Tyr, R3 is Leu and R4 is ethyl.
7. The compound as claimed in claim 1, wherein R1 is His, R2 is Tyr, R3 is Leu and R4 is n-propyl.
8. The compound as claimed in claim 1, wherein R1 is His, R2 is Tyr, R3 is Leu and R4 is 2-hydroxyethyl.
9. The compound as claimed in claim 1, wherein R1 is His, R2 is Tyr, R3 is Leu and R4 is i-propyl.
10. The compound as claimed in claim 1, wherein R1 is His, R2 is Phe, R3 is Leu and R4 is ethyl.
11. The compound as claimed in claim 1, wherein R1 is His, R2 is Tyr, R3 is Nle and R4 is ethyl group.
12. The compound as claimed in claim 1, wherein R1 is His, R2 is Phe, R3 is Ile and R4 is ethyl group.
13. The compound as claimed in claim 1, wherein R1 is Tyr, R2 is Tyr, R3 is Leu and R4 is ethyl group.
14. The compound as claimed in claim 1, wherein R1 is p--NH2 --Phe, R2 is Tyr, R3 is Leu and R4 is ethyl.
15. A compound as claimed in claim 1 wherein R2 is Phe.
16. A compound as claimed in claim 1 wherein R2 is Tyr and R4 is alkyl of 3 carbon atoms.
17. A compound as claimed in claim 1 wherein R2 is Tyr, and R4 is --CH2 CH2 OH.
18. A compound of the formula
(Pyr)Glu--His--Trp--Ser--Tyr--D--Ala--Leu--Arg--Pro--X
wherein X is NHCH2 CH3 or NHCH2 CH2 CH3.
US05/596,810 1973-07-24 1975-07-17 Nonapeptide amides Expired - Lifetime US4490291A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP8338973A JPS5035158A (en) 1973-07-24 1973-07-24
JP83389 1973-07-24
JP49031734A JPS5749532B2 (en) 1974-03-19 1974-03-19
JP31734 1974-03-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US05491482 Continuation 1974-07-24

Publications (1)

Publication Number Publication Date
US4490291A true US4490291A (en) 1984-12-25

Family

ID=26370246

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/596,810 Expired - Lifetime US4490291A (en) 1973-07-24 1975-07-17 Nonapeptide amides

Country Status (16)

Country Link
US (1) US4490291A (en)
AT (1) AT347053B (en)
BE (1) BE817989A (en)
CA (1) CA1030525A (en)
CH (1) CH611877A5 (en)
CS (1) CS186785B2 (en)
DE (1) DE2435027C2 (en)
DK (1) DK148304C (en)
ES (1) ES428530A1 (en)
FI (1) FI60553C (en)
FR (1) FR2238700B1 (en)
GB (1) GB1423083A (en)
HU (1) HU173662B (en)
NL (1) NL184161B (en)
NO (1) NO140854C (en)
SE (1) SE401822B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4691008A (en) * 1984-03-27 1987-09-01 Hoechst Aktiengesellschaft Process for the low-racemization preparation of peptide intermediates of the synthesis of gonadorelin and gonadorelin analogs, and new intermediates for this process
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US20040132179A1 (en) * 2000-10-13 2004-07-08 Richard Boyd Treatment of t cell disorders
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20060229251A1 (en) * 2000-10-13 2006-10-12 Monash University Treatment of T cell disorders
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491541A (en) * 1982-11-10 1985-01-01 Farmitalia Carlo Erba Peptides
GB2130590B (en) * 1982-11-10 1986-01-08 Erba Farmitalia Peptides
IT1172391B (en) * 1983-12-23 1987-06-18 Polifarma Spa TYRPEPTID COMPOUNDS CONTAINING PYROGLUTAMINIC ACID AND TRIPTOPHAN, PRODUCTION PROCEDURE AND THERAPEUTIC APPLICATIONS
CA2029018A1 (en) * 1989-11-01 1991-05-02 Robert P. Millar Analogues of gonadotropin releasing hormone
JP2653255B2 (en) 1990-02-13 1997-09-17 武田薬品工業株式会社 Long-term sustained release microcapsules
CA2050425A1 (en) 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
NO302481B1 (en) 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for an extended release preparation, as well as an extended release preparation
DE69316101T2 (en) 1992-08-07 1998-10-22 Takeda Chemical Industries Ltd Manufacture of microcapsules containing water-soluble drugs
ATE211655T1 (en) 1993-09-22 2002-01-15 Hisamitsu Pharmaceutical Co IONTOPHORESIS MATRIX
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
EP0813887A3 (en) * 1996-06-20 1999-11-03 Hisamitsu Pharmaceutical Co. Inc. A device structure for iontophoresis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. H. Coy, et al., Biochem. and Biophys. Res. Comm. 57, 1974, pp. 335 340. *
D. H. Coy, et al., Biochem. and Biophys. Res. Comm. 57, 1974, pp. 335-340.

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4691008A (en) * 1984-03-27 1987-09-01 Hoechst Aktiengesellschaft Process for the low-racemization preparation of peptide intermediates of the synthesis of gonadorelin and gonadorelin analogs, and new intermediates for this process
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040132179A1 (en) * 2000-10-13 2004-07-08 Richard Boyd Treatment of t cell disorders
US20060229251A1 (en) * 2000-10-13 2006-10-12 Monash University Treatment of T cell disorders
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation

Also Published As

Publication number Publication date
GB1423083A (en) 1976-01-28
NL7410026A (en) 1975-01-28
AT347053B (en) 1978-12-11
CH611877A5 (en) 1979-06-29
HU173662B (en) 1979-07-28
FI60553C (en) 1982-02-10
NL184161B (en) 1988-12-01
DE2435027C2 (en) 1981-11-26
FI60553B (en) 1981-10-30
ATA605674A (en) 1978-04-15
CS186785B2 (en) 1978-12-29
DK393674A (en) 1975-03-17
CA1030525A (en) 1978-05-02
NO140854C (en) 1979-11-28
BE817989A (en) 1975-01-23
FI224374A (en) 1975-01-25
NO140854B (en) 1979-08-20
NO742690L (en) 1975-03-17
FR2238700B1 (en) 1977-10-14
DK148304B (en) 1985-06-03
SE401822B (en) 1978-05-29
SE7409574L (en) 1975-01-27
AU7124574A (en) 1976-01-15
DK148304C (en) 1985-11-04
FR2238700A1 (en) 1975-02-21
ES428530A1 (en) 1976-08-16
DE2435027A1 (en) 1975-02-06

Similar Documents

Publication Publication Date Title
US4490291A (en) Nonapeptide amides
US4008209A (en) Nonapeptide amide analogs of luteinizing releasing hormone
US3972859A (en) Novel decapeptide amide analogs of leuteinizing hormone-releasing hormone
US3853837A (en) Novel nonapeptide amide analogs of luteinizing hormone releasing factor
US4118483A (en) Peptides having gonadoliberin activity and process for their manufacture
US3992365A (en) Agonist analogues of luteinizing hormone releasing hormone
US4024248A (en) Peptides having LH-RH/FSH-RH activity
JP2542362B2 (en) Novel halo lower alkyl guanidino substituted amino acid compound and process for producing the same
WO1983004250A1 (en) Gonadoliberin derivatives, process for the preparation and pharmaceutical and veterinary compositions thereof
EP0106404B1 (en) Peptides
US4075191A (en) Biologically active amides
US3749703A (en) Asn15-bovine thyrocalcitonin
US4083967A (en) Nona- and decapeptides
DK164875B (en) GONADOLIBERIN DERIVATIVES AND THEIR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS OR METAL COMPLEXES, A PROCEDURE FOR PREPARING THEM AND A PHARMACEUTICAL PREPARATION CONTAINING THESE
Inouye et al. A synthesis of thyrotropin-releasing factor
JPH0631314B2 (en) Novel gonadobereline derivative
US4001199A (en) Novel polypeptides useful for treating diabetes and hypercholesteremia
US3826794A (en) Protected decapeptide derivatives of gonadotropin releasing hormone
US4358440A (en) Polypeptide and its production and use
RU2086561C1 (en) Method for production of nonapeptide ethyl amide
US4101537A (en) Octapeptides and methods for their production
US3234201A (en) Octadecapeptides and derivatives thereof
US4073890A (en) Novel polypeptides
Burov et al. Synthesis and investigation of the biological activity of shortened analogues of luliberin
DK149755B (en) METHOD OF ANALOGY FOR THE PREPARATION OF LHRH ANALOGUE NONAPEPTIDAMIDE DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS OR METAL COMPLEXES THEREOF

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE